Status:
COMPLETED
Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients
Lead Sponsor:
AstraZeneca
Conditions:
Non Small Cell Lung Cancer
Eligibility:
MALE
20+ years
Brief Summary
The objective is to investigate the correlation between smoking pattern and clinical efficacy of EGFR TKIs in male patients with locally advanced or metastasized non-small cell lung cancer of adeno hi...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male patients age 20 years or older
- Histological or cytological confirmation of NSCLC of adeno histology. If sputum is the only available sample, a second positive test is necessary for cytological confirmation
- Locally advanced or metastatic on or after first-line chemotherapy. Imaging evidence of disease progression can be either chest X ray, CT or MRI assessment on measurable lesions. If no measurable lesion is available, evaluable lesions are acceptable
Exclusion
Key Trial Info
Start Date :
August 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT00922025
Start Date
August 1 2009
End Date
December 1 2010
Last Update
September 27 2011
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Changhua, Taiwan
2
Research Site
Chiayi City, Taiwan
3
Research Site
Kaohsiung City, Taiwan
4
Research Site
Taichung, Taiwan